Literature DB >> 32591463

IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.

Joe-Marc Chauvin1, Mignane Ka1, Ornella Pagliano1, Carmine Menna1, Quanquan Ding1, Richelle DeBlasio1, Cindy Sanders1, Jiajie Hou2, Xian-Yang Li3, Soldano Ferrone4, Diwakar Davar1, John M Kirkwood1, Robert J Johnston5, Alan J Korman5, Mark J Smyth3, Hassane M Zarour6,7.   

Abstract

PURPOSE: Natural killer (NK) cells play a critical role in tumor immunosurveillance. Multiple activating and inhibitory receptors (IR) regulate NK-cell-mediated tumor control. The IR T-cell immunoglobulin and ITIM domain (TIGIT) and its counter-receptor CD226 exert opposite effects on NK-cell-mediated tumor reactivity. EXPERIMENTAL
DESIGN: We evaluated the frequency, phenotype, and functions of NK cells freshly isolated from healthy donors and patients with melanoma with multiparameter flow cytometry. We assessed TIGIT and CD226 cell surface expression and internalization upon binding to CD155. We evaluated the role of IL15 and TIGIT blockade in increasing NK-cell-mediated cytotoxicity in vitro and in two mouse models.
RESULTS: NK cells are present at low frequencies in metastatic melanoma, are dysfunctional, and downregulate both TIGIT and CD226 expression. As compared with TIGIT- NK cells, TIGIT+ NK cells exhibit higher cytotoxic capacity and maturation, but paradoxically lower cytotoxicity against CD155+ MHC class I-deficient melanoma cells. Membrane bound CD155 triggers CD226 internalization and degradation, resulting in decreased NK-cell-mediated tumor reactivity. IL15 increases TIGIT and CD226 gene expression by tumor-infiltrating NK cells (TiNKs) and, together with TIGIT blockade, increases NK-cell-mediated melanoma cytotoxicity in vitro and decreases tumor metastasis in two mouse melanoma models. Specific deletion of TIGIT on transferred NK cells enhances the antimetastatic activity of IL15, while CD226 blockade decreases the effects of IL15 and TIGIT blockade.
CONCLUSIONS: Our findings support the development of novel combinatorial immunotherapy with IL15 and TIGIT blockade to promote NK-cell-mediated destruction of MHC class I-deficient melanoma, which are refractory to CD8+ T-cell-mediated immunity.See related commentary by Pietra et al., p. 5274. ©2020 American Association for Cancer Research.

Entities:  

Year:  2020        PMID: 32591463      PMCID: PMC8045409          DOI: 10.1158/1078-0432.CCR-20-0575

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  59 in total

1.  Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity.

Authors:  Lishomwa C Ndhlovu; Sandra Lopez-Vergès; Jason D Barbour; R Brad Jones; Aashish R Jha; Brian R Long; Eric C Schoeffler; Tsuyoshi Fujita; Douglas F Nixon; Lewis L Lanier
Journal:  Blood       Date:  2012-03-01       Impact factor: 22.113

2.  Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma.

Authors:  Sophia Platonova; Julien Cherfils-Vicini; Diane Damotte; Lucile Crozet; Vincent Vieillard; Pierre Validire; Pascale André; Marie-Caroline Dieu-Nosjean; Marco Alifano; Jean-François Régnard; Wolf-Herman Fridman; Catherine Sautès-Fridman; Isabelle Cremer
Journal:  Cancer Res       Date:  2011-06-27       Impact factor: 12.701

3.  Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation.

Authors:  Veronika Groh; Jennifer Wu; Cassian Yee; Thomas Spies
Journal:  Nature       Date:  2002-10-17       Impact factor: 49.962

4.  NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells.

Authors:  H M Zarour; W J Storkus; V Brusic; E Williams; J M Kirkwood
Journal:  Cancer Res       Date:  2000-09-01       Impact factor: 12.701

5.  Inherent and Tumor-Driven Immune Tolerance in the Prostate Microenvironment Impairs Natural Killer Cell Antitumor Activity.

Authors:  Christine Pasero; Gwenaëlle Gravis; Mathilde Guerin; Samuel Granjeaud; Jeanne Thomassin-Piana; Palma Rocchi; Maria Paciencia-Gros; Flora Poizat; Mélanie Bentobji; Francine Azario-Cheillan; Jochen Walz; Naji Salem; Serge Brunelle; Alessandro Moretta; Daniel Olive
Journal:  Cancer Res       Date:  2016-04-05       Impact factor: 12.701

6.  TIGIT predominantly regulates the immune response via regulatory T cells.

Authors:  Sema Kurtulus; Kaori Sakuishi; Shin-Foong Ngiow; Nicole Joller; Dewar J Tan; Michele W L Teng; Mark J Smyth; Vijay K Kuchroo; Ana C Anderson
Journal:  J Clin Invest       Date:  2015-09-28       Impact factor: 14.808

7.  Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect.

Authors:  Martin Felices; Alexander J Lenvik; Ron McElmurry; Sami Chu; Peter Hinderlie; Laura Bendzick; Melissa A Geller; Jakub Tolar; Bruce R Blazar; Jeffrey S Miller
Journal:  JCI Insight       Date:  2018-02-08

8.  Combination cancer immunotherapy targeting PD-1 and GITR can rescue CD8+ T cell dysfunction and maintain memory phenotype.

Authors:  Bei Wang; Wen Zhang; Vladimir Jankovic; Jacquelynn Golubov; Patrick Poon; Erin M Oswald; Cagan Gurer; Joyce Wei; Ilyssa Ramos; Qi Wu; Janelle Waite; Min Ni; Christina Adler; Yi Wei; Lynn Macdonald; Tracey Rowlands; Susannah Brydges; Jean Siao; William Poueymirou; Douglas MacDonald; George D Yancopoulos; Matthew A Sleeman; Andrew J Murphy; Dimitris Skokos
Journal:  Sci Immunol       Date:  2018-11-02

9.  Increased levels of soluble CD226 in sera accompanied by decreased membrane CD226 expression on peripheral blood mononuclear cells from cancer patients.

Authors:  Zhuwei Xu; Tao Zhang; Ran Zhuang; Yun Zhang; Wei Jia; Chaojun Song; Kun Yang; Angang Yang; Boquan Jin
Journal:  BMC Immunol       Date:  2009-06-02       Impact factor: 3.615

10.  Induction and transcriptional regulation of the co-inhibitory gene module in T cells.

Authors:  Norio Chihara; Asaf Madi; Takaaki Kondo; Huiyuan Zhang; Nandini Acharya; Meromit Singer; Jackson Nyman; Nemanja D Marjanovic; Monika S Kowalczyk; Chao Wang; Sema Kurtulus; Travis Law; Yasaman Etminan; James Nevin; Christopher D Buckley; Patrick R Burkett; Jason D Buenrostro; Orit Rozenblatt-Rosen; Ana C Anderson; Aviv Regev; Vijay K Kuchroo
Journal:  Nature       Date:  2018-06-13       Impact factor: 49.962

View more
  30 in total

Review 1.  Targeting novel inhibitory receptors in cancer immunotherapy.

Authors:  Quan-Quan Ding; Joe-Marc Chauvin; Hassane M Zarour
Journal:  Semin Immunol       Date:  2020-12-04       Impact factor: 11.130

2.  Enhanced development of functional human NK cells in NOD-scid-IL2rgnull mice expressing human IL15.

Authors:  Ken-Edwin Aryee; Lisa M Burzenski; Li-Chin Yao; James G Keck; Dale L Greiner; Leonard D Shultz; Michael A Brehm
Journal:  FASEB J       Date:  2022-09       Impact factor: 5.834

Review 3.  Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders.

Authors:  Nicholas A Maskalenko; Dmitry Zhigarev; Kerry S Campbell
Journal:  Nat Rev Drug Discov       Date:  2022-03-21       Impact factor: 112.288

Review 4.  Emerging concepts in PD-1 checkpoint biology.

Authors:  Kristen E Pauken; James A Torchia; Apoorvi Chaudhri; Arlene H Sharpe; Gordon J Freeman
Journal:  Semin Immunol       Date:  2021-05-15       Impact factor: 11.130

5.  SPaRTAN, a computational framework for linking cell-surface receptors to transcriptional regulators.

Authors:  Xiaojun Ma; Ashwin Somasundaram; Zengbiao Qi; Douglas J Hartman; Harinder Singh; Hatice Ulku Osmanbeyoglu
Journal:  Nucleic Acids Res       Date:  2021-09-27       Impact factor: 16.971

Review 6.  TIGIT in cancer immunotherapy.

Authors:  Joe-Marc Chauvin; Hassane M Zarour
Journal:  J Immunother Cancer       Date:  2020-09       Impact factor: 13.751

Review 7.  Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer.

Authors:  Sara E Nunnery; Ingrid A Mayer
Journal:  Drugs       Date:  2020-11       Impact factor: 9.546

Review 8.  Natural killer cells in cancer biology and therapy.

Authors:  Song-Yang Wu; Tong Fu; Yi-Zhou Jiang; Zhi-Ming Shao
Journal:  Mol Cancer       Date:  2020-08-06       Impact factor: 27.401

9.  A Poliovirus Receptor (CD155)-Related Risk Signature Predicts the Prognosis of Bladder Cancer.

Authors:  Cong Luo; Wenrui Ye; Jiao Hu; Belaydi Othmane; Huihuang Li; Jinbo Chen; Xiongbing Zu
Journal:  Front Oncol       Date:  2021-06-03       Impact factor: 6.244

Review 10.  Detection of Immune Checkpoint Receptors - A Current Challenge in Clinical Flow Cytometry.

Authors:  Benjamin Shibru; Katharina Fey; Stephan Fricke; André-René Blaudszun; Friederike Fürst; Max Weise; Sabine Seiffert; Maria Katharina Weyh; Ulrike Köhl; Ulrich Sack; Andreas Boldt
Journal:  Front Immunol       Date:  2021-07-01       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.